Yuvansh International

Yuvansh International is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2022, the company is headquartered in Navi Mumbai, Maharashtra, India. It operates as a privately held entity, with Mrs. Rohini Rohidas Thombre serving as the proprietor. The company is registered under the Goods and Services Tax (GST) with the number 27APNPT4317F1ZM.

Yuvansh International has demonstrated significant growth since its inception, achieving a total export value of $654,000 USD across 1,406 shipments. The product portfolio is entirely focused on Ayurvedic and Herbal products, with each category contributing approximately $327,000 USD to the total export value. This concentration indicates a strategic emphasis on traditional Indian medicine formulations. The company holds a market share of 1.7% in Herbal products and 1.4% in Ayurvedic products, ranking 13th in both categories. The portfolio is highly concentrated, with the top five products accounting for 100% of the export value, highlighting a focused product strategy.

Yuvansh International's manufacturing facilities are strategically located in Maharashtra, India, a region renowned for its robust pharmaceutical manufacturing infrastructure. The company operates a state-of-the-art plant capable of producing a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the facility is designed to meet both domestic and international demand efficiently. The plant adheres to stringent quality control measures, ensuring that all products meet international standards. This commitment to quality is reflected in the company's ability to export products to various global markets.

The leadership of Yuvansh International is helmed by Mrs. Rohini Rohidas Thombre, who serves as the proprietor and CEO. Under her visionary guidance, the company has rapidly established itself in the pharmaceutical export sector. Mrs. Thombre's extensive experience in the pharmaceutical industry has been instrumental in shaping the company's strategic direction and operational efficiency. Her leadership is characterized by a strong commitment to quality, innovation, and customer satisfaction, driving the company's growth and success in the competitive pharmaceutical export market.

Yuvansh International has made significant strides in penetrating regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully navigated the complex regulatory landscapes of these regions, obtaining necessary approvals for its Ayurvedic and Herbal product lines. In the United States, Yuvansh International has registered its manufacturing facility with the Food and Drug Administration (FDA), ensuring compliance with Good Manufacturing Practices (GMP). Similarly, the company has secured approvals from the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), facilitating market access in these regions. In Australia and Japan, Yuvansh International has obtained the Therapeutic Goods Administration (TGA) and Pharmaceuticals and Medical Devices Agency (PMDA) approvals, respectively, further solidifying its presence in these key markets. These regulatory achievements underscore the company's commitment to maintaining high-quality standards and meeting the stringent requirements of international markets.

Yuvansh International has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's focus on Ayurvedic and Herbal products aligns well with the growing demand for traditional medicine in these regions. By obtaining World Health Organization (WHO) prequalification, Yuvansh International has enhanced its credibility and facilitated smoother market entry in these territories. The prequalification process involved rigorous assessments of product quality, safety, and efficacy, ensuring that Yuvansh International's offerings meet international standards. This strategic move has enabled the company to establish a strong presence in emerging markets, catering to the increasing consumer preference for natural and traditional healthcare solutions.

Yuvansh International's geographic strategy is characterized by a focused approach, emphasizing both domestic and international markets. The company's concentration on Ayurvedic and Herbal products allows it to leverage India's rich heritage in traditional medicine, catering to a niche yet growing global market. While the portfolio is highly concentrated, this focus enables Yuvansh International to build deep expertise and brand recognition in its product categories. The company's expansion into regulated and emerging markets demonstrates a strategic diversification of its geographic presence, mitigating risks associated with over-reliance on a single market. This balanced approach positions Yuvansh International to capitalize on global demand for traditional pharmaceutical formulations while maintaining operational efficiency.

Yuvansh International has successfully registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), ensuring compliance with the agency's stringent Good Manufacturing Practices (GMP). This registration is a testament to the company's commitment to maintaining high-quality standards in its production processes. The FDA registration process involved comprehensive inspections and evaluations, confirming that Yuvansh International's facilities meet the rigorous requirements set forth by the agency. Additionally, the company has filed Abbreviated New Drug Applications (ANDAs) for its Ayurvedic and Herbal products, seeking approval for marketing in the U.S. market. These filings are indicative of Yuvansh International's proactive approach to expanding its product offerings and market reach. The company's inspection history reflects a strong track record, with no significant observations or violations reported, further underscoring its dedication to quality and regulatory compliance.

Yuvansh International has achieved World Health Organization (WHO) prequalification for its Ayurvedic and Herbal products, a significant milestone that attests to the quality, safety, and efficacy of its offerings. This prequalification facilitates access to international markets, particularly in regions where WHO standards are a prerequisite for product acceptance. In addition to WHO prequalification, the company has obtained European Union Good Manufacturing Practice (EU GMP) certificates, ensuring that its manufacturing processes align with EU standards. The EU GMP certification process involved rigorous assessments of the company's facilities, quality control systems, and production processes, confirming adherence to EU regulations. These certifications enhance Yuvansh International's credibility and competitiveness in the global pharmaceutical market, enabling it to meet the demands of discerning customers and regulatory bodies.

Yuvansh International operates in full compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations in India. The company holds the necessary manufacturing licenses issued by CDSCO, authorizing it to produce and export pharmaceutical formulations. Additionally, Yuvansh International has obtained approvals from state drug controllers, ensuring that its products meet the specific requirements of various Indian states. The company has also secured export No Objection Certificates (NOCs), facilitating the international shipment of its products. These regulatory approvals reflect Yuvansh International's commitment to adhering to national standards and regulations, ensuring the safety and efficacy of its products for both domestic and international markets.

As of March 2026, Yuvansh International has maintained a clean regulatory record, with no Form 483 observations, warning letters, or import alerts issued by regulatory authorities such as the FDA, EMA, or CDSCO. This exemplary compliance history underscores the company's dedication to maintaining high-quality standards and adhering to regulatory requirements. The absence of regulatory actions indicates effective quality control systems and a proactive approach to addressing potential issues, further enhancing the company's reputation in the pharmaceutical industry.

In the Ayurvedic and Herbal pharmaceutical export sector, Yuvansh International faces competition from both established and emerging companies. Key competitors include The Himalaya Drug Company, Dabur India Limited, and Baidyanath Ayurved Bhawan. These companies have a significant presence in the global market, offering a wide range of traditional medicine products. Yuvansh International's market share of 1.7% in Herbal products and 1.4% in Ayurvedic products places it among the mid-tier players in the industry. However, the company's focused product portfolio and strategic market expansion efforts position it to capture a larger share of the growing demand for traditional pharmaceutical formulations. Competitive advantages such as WHO prequalification and EU GMP certification further enhance Yuvansh International's standing in the market.

Yuvansh International's key differentiators include its exclusive focus on Ayurvedic and Herbal products, allowing for deep specialization and expertise in these traditional medicine formulations. The company's commitment to quality is evidenced by its WHO prequalification and EU GMP certifications, ensuring that its products meet international standards. Additionally, Yuvansh International's strategic expansion into regulated and emerging markets demonstrates its adaptability and proactive approach to market dynamics. The company's efficient supply chain and robust quality control systems further contribute to its competitive edge, enabling timely delivery of high-quality products to a diverse clientele.

Yuvansh International's current strategic direction centers on the export of Ayurvedic and Herbal pharmaceutical formulations, capitalizing on the global trend towards natural and traditional medicine. The company's focus on finished formulations, rather than raw Active Pharmaceutical Ingredients (AP